Intelligent healthcare through single molecule diagnostics
BillionToOne (billiontoone.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, in the 49th percentile of 7760 Healthcare brands.
BillionToOne is a healthcare technology company based in Menlo Park, United States, founded in 2016. It develops single molecule diagnostics using cell-free DNA from a single blood draw to advance non-invasive prenatal screening and cancer liquid biopsy. The company positions itself as a leader in disease detection, serving healthcare providers, oncologists, obstetricians, and patients seeking accurate, actionable diagnostic insights.
| Brand Name | BillionToOne |
|---|---|
| Domain | billiontoone.com |
| Industry | Healthcare, Technology |
| Founded | 2016 |
| Headquarters | Menlo Park, United States |
| Main Competitors | Natera (85/100), Guardant Health (87/100), Exact Sciences (84/100), GRAIL (90/100), Labcorp (77/100), Myriad Genetics (83/100) |
Moz Domain Authority 34/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #535,995 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward." (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is BillionToOne?", Claude could identify the brand as of September 2026. BillionToOne is a molecular diagnostics company best known for its non-invasive prenatal testing technology, using a proprietary molecular counting approach to detect fetal genetic conditions from maternal blood. Best known for UNITY, its non-invasive prenatal screening test that uses molecular counting to detect conditions like sickle cell disease and cystic fibrosis alongside standar.
When asked "Best brands similar to BillionToOne?", Claude would recommend BillionToOne as of September 2026. It's a notable player in the prenatal genetic testing space with a distinctive molecular counting technology that differentiates it from competitors like Natera and Illumina-based NIPT providers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
BillionToOne's main competitors in Healthcare: Natera (85/100), Guardant Health (87/100), Exact Sciences (84/100), GRAIL (90/100), Labcorp (77/100).
Sources: Brand Analyzer scan
BillionToOne has limited AI-search visibility, scoring 29/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 19, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: BillionToOne official site
BillionToOne was founded in 2016. BillionToOne operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
BillionToOne scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: BillionToOne official site
BillionToOne is a healthcare technology company founded in 2016 and headquartered in Menlo Park, United States. It specializes in disease detection diagnostics, focusing on prenatal screening and cancer liquid biopsy using proprietary single molecule counting technology applied to cell-free DNA.
Sources: BillionToOne official site
BillionToOne develops and provides non-invasive diagnostic tests based on single molecule counting technology with cell-free DNA. These tests are designed to deliver highly accurate, actionable insights from a single blood draw, supporting prenatal screening and cancer liquid biopsy applications for healthcare providers and patients.
Sources: BillionToOne official site
BillionToOne can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: BillionToOne official site
BillionToOne offers non-invasive prenatal screening tests and cancer liquid biopsy diagnostics, both built on its proprietary single molecule counting technology applied to cell-free DNA obtained from a single blood draw. These tests are designed to provide accurate, actionable diagnostic insights for both prenatal care and cancer detection and monitoring.
Sources: BillionToOne official site
BillionToOne is known for pioneering single molecule diagnostics technology that uses cell-free DNA from a single blood draw to advance non-invasive prenatal screening and cancer liquid biopsy testing, positioning itself as offering greater accuracy and clinical utility than traditional diagnostic methods.
Sources: BillionToOne official site
BillionToOne's tests are used by healthcare providers, including obstetricians and oncologists, as well as patients seeking non-invasive prenatal screening or cancer diagnostic and monitoring solutions.
Sources: BillionToOne official site
BillionToOne scores 29/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
BillionToOne has a weak AI-visibility profile at 29/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is trust (19/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #535,995 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and thin schema.org structured data. In a live check, Claude could already identify BillionToOne from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to BillionToOne: BetterRX (76/100), Belmont Dental Equipment (76/100), BioNTech (76/100), BioT (76/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), ZOLL Data Systems (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.